HIGHLIGHTS
- who: Naminatsu Takahara from the Department of Hepatobiliary and Pancreatic, National Center Hospital East, Kashiwa, Japan of Medicine, The University of Tokyo, Tokyo, Japan have published the research: A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer, in the Journal: (JOURNAL)
- how: The authors designed this prospective study to evaluate safety and efficacy of FOLFIRINOX in patients with chemotherapynau00efve advanced or recurrent BTC. This study was conducted in accordance with the Declaration of Helsinki and the guidelines of Good Clinical Practice.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.